Festive Features: Hybridan analyst Nathan on what to look for in a biotech investment




Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 30, 2014

Derren Nathan, lead analyst at Hybridan, says there is demand from investors for companies with revenues and diversified later-stage portfolios. Nathan likes the look of Toronto-listed ProMetic Life Sciences (TSE:PLI) and Bellus Health (TSE:BLU), as well as AIM-listed Sareum Holdings (LON:SAR) and recent AIM float OptiBiotix Health (LON:OPTI).

Comments are disabled for this video.
When autoplay is enabled, a suggested video will automatically play next.

Up next

to add this to Watch Later

Add to

Loading playlists...